Published on
February 12, 2026
- 00:00 GMT
LexBio Therapeutics and Hiteck Announce Strategic Collaboration to Advance Novel Therapies for Inflammatory Disorders
LexBio and Hiteck partner to develop novel drug candidates using AI-driven molecular glue degraders targeting B- and T-cell pathways for immune-related diseases SUZHOU, JIANGSU, CHINA, February 11, 2026 /EINPresswire.com/ -- LexBio Therapeutics (“LexBio …
Distribution channels:
Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry
...
